Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

WAYNE, Pa. - Palvella Therapeutics Inc. (NASDAQ:PVLA), whose stock has gained nearly 19% year-to-date and currently trades at $14.25, announced today that results from its Phase 2... ByInvesting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations were published in the Journal ...

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...

Pieris Pharmaceuticals (NASDAQ:PIRS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2020. This ...

Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin ...

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ ... Palvella Therapeutics Inc. - (GLOBE NEWSWIRE) Jan 8, 2025 ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic ...

On Friday, H.C. Wainwright reaffirmed a positive stance on Palvella Therapeutics (NASDAQ:PVLA) shares, maintaining a Buy rating and a price target of $38.00. The endorsement comes with a focus on the ...